Leonard Zehr, Author at BioTuesdays

Feature

MAIA telomere-targeting technology aiming at therapy-resistant tumors

MAIA Biotechnology (NYSE American:MAIA) is developing a telomere-targeting immunotherapy, THIO, with a dual mechanism of action, that can be used in sequential combination with existing immune therapies to target cancer.

November 15, 2022

Feature

Miromatrix bioengineering human organs to eliminate waitlists

With the need for organs for transplantation far exceeding the supply and creating long waitlists, Miromatrix Medical (NASDAQ:MIRO) is bioengineering human organs with the potential to eliminate the transplant waitlists.

November 8, 2022

Developments

iBio accelerates transformation to AI-powered biotech

iBio (NYSEA:IBIO) announced it is seeking to divest its contract development and manufacturing organization, iBio CDMO, in order to complete its transformation into an antibody discovery and development company...

November 3, 2022

Feature

Comera working to transform biologics to SQ injections from IV delivery

Comera Life Sciences (NASDAQ:CMRA) is using a proprietary excipient formulation platform, known as SQore, to potentially transform intravenous (IV) biologics into subcutaneous (SQ) versions that patients can self...

November 1, 2022

Feature

Atossa Therapeutics pivots inhalation therapy from COVID-19 to oncology

With widespread availability of SARS-CoV-2 vaccines and other therapies now approved to treat COVID-19, Atossa Therapeutics (NASDAQ:ATOS) has pivoted development of its AT-H201 inhalation therapy to cancer patients with...

October 25, 2022

Feature

OpSens SavvyWire tackling cardiology with advanced optical devices

With last month’s FDA clearance of the SavvyWire transcatheter aortic valve replacement (TAVR) guidewire, OpSens (TSX:OPS; OTCQX:OPSSF) is bringing a new concept to interventional cardiology and the delivery of new...

October 18, 2022

Feature

VoxNeuro is giving the brain a voice through cognitive health assessment

VoxNeuro’s software as a medical device (SaMD) is transforming cognitive health assessment as it pushes the boundaries of our understanding of the brain to improve decision-making by clinicians and patients.

October 11, 2022

Feature

Sigyn Therapeutics outlines first-in-human clinical strategy for its novel blood purification technology

Sigyn Therapeutics (OTCQB:SIGY) has transitioned its Sigyn Therapy blood-purification device from conceptual design two years ago to preparing to initiate its first-in-human studies in end-stage renal disease patients...

October 4, 2022

Developments

VoxNeuro, CAF in study to measure training-related sub-concussive exposure

VoxNeuro, a closely-held software-as-a-medical-device (SaMD) brain health company, has partnered with the Canadian Armed Forces (CAF) to study the cognitive effects following intense military training regimens designed...

September 28, 2022

Feature

Kiora Pharma eyes novel approach to vision restoration in retinitis pigmentosa

Kiora Pharmaceuticals (NASDAQ:KPRX) expects to release Phase 1b interim data at the beginning of 2023 from its flagship intravitreal injection to potentially restore vision in patients with retinitis pigmentosa, a rare...

September 27, 2022

Author - Leonard Zehr

MAIA telomere-targeting technology aiming at therapy-resistant tumors

Miromatrix bioengineering human organs to eliminate waitlists

iBio accelerates transformation to AI-powered biotech

Comera working to transform biologics to SQ injections from IV delivery

Atossa Therapeutics pivots inhalation therapy from COVID-19 to oncology

OpSens SavvyWire tackling cardiology with advanced optical devices

VoxNeuro is giving the brain a voice through cognitive health assessment

Sigyn Therapeutics outlines first-in-human clinical strategy for its novel blood purification technology

VoxNeuro, CAF in study to measure training-related sub-concussive exposure

Kiora Pharma eyes novel approach to vision restoration in retinitis pigmentosa

General

More